Cargando…

A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys

BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoer, Saar, Karady, Tal, Keshet, Ayya, Shilo, Smadar, Rossman, Hagai, Gavrieli, Amir, Meir, Tomer, Lavon, Amit, Kolobkov, Dmitry, Kalka, Iris, Godneva, Anastasia, Cohen, Ori, Kariv, Adam, Hoch, Ori, Zer-Aviv, Mushon, Castel, Noam, Sudre, Carole, Zohar, Anat Ekka, Irony, Angela, Spector, Tim, Geiger, Benjamin, Hizi, Dorit, Shalev, Varda, Balicer, Ran, Segal, Eran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547576/
https://www.ncbi.nlm.nih.gov/pubmed/33073258
http://dx.doi.org/10.1016/j.medj.2020.10.002
_version_ 1783592449323565056
author Shoer, Saar
Karady, Tal
Keshet, Ayya
Shilo, Smadar
Rossman, Hagai
Gavrieli, Amir
Meir, Tomer
Lavon, Amit
Kolobkov, Dmitry
Kalka, Iris
Godneva, Anastasia
Cohen, Ori
Kariv, Adam
Hoch, Ori
Zer-Aviv, Mushon
Castel, Noam
Sudre, Carole
Zohar, Anat Ekka
Irony, Angela
Spector, Tim
Geiger, Benjamin
Hizi, Dorit
Shalev, Varda
Balicer, Ran
Segal, Eran
author_facet Shoer, Saar
Karady, Tal
Keshet, Ayya
Shilo, Smadar
Rossman, Hagai
Gavrieli, Amir
Meir, Tomer
Lavon, Amit
Kolobkov, Dmitry
Kalka, Iris
Godneva, Anastasia
Cohen, Ori
Kariv, Adam
Hoch, Ori
Zer-Aviv, Mushon
Castel, Noam
Sudre, Carole
Zohar, Anat Ekka
Irony, Angela
Spector, Tim
Geiger, Benjamin
Hizi, Dorit
Shalev, Varda
Balicer, Ran
Segal, Eran
author_sort Shoer, Saar
collection PubMed
description BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions that have been associated with SARS-CoV-2 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel in its first 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. FINDINGS: Our model was validated on a held-out set of individuals from Israel where it achieved an auROC of 0.737 (CI: 0.712–0.759) and auPR of 0.144 (CI: 0.119–0.177) and demonstrated its applicability outside of Israel in an independently collected symptom survey dataset from the US, UK, and Sweden. Our analyses revealed interactions between several symptoms and age, suggesting variation in the clinical manifestation of the disease in different age groups. CONCLUSIONS: Our tool can be used online and without exposure to suspected patients, thus suggesting worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified. Moreover, individuals at high risk for a positive test result can be isolated prior to testing. FUNDING: E.S. is supported by the Crown Human Genome Center, Larson Charitable Foundation New Scientist Fund, Else Kroener Fresenius Foundation, White Rose International Foundation, Ben B. and Joyce E. Eisenberg Foundation, Nissenbaum Family, Marcos Pinheiro de Andrade and Vanessa Buchheim, Lady Michelle Michels, and Aliza Moussaieff and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation. H.R. is supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein – Astrachan.
format Online
Article
Text
id pubmed-7547576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-75475762020-10-13 A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys Shoer, Saar Karady, Tal Keshet, Ayya Shilo, Smadar Rossman, Hagai Gavrieli, Amir Meir, Tomer Lavon, Amit Kolobkov, Dmitry Kalka, Iris Godneva, Anastasia Cohen, Ori Kariv, Adam Hoch, Ori Zer-Aviv, Mushon Castel, Noam Sudre, Carole Zohar, Anat Ekka Irony, Angela Spector, Tim Geiger, Benjamin Hizi, Dorit Shalev, Varda Balicer, Ran Segal, Eran Med (N Y) Clinical and Translational Resource and Technology Insights BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions that have been associated with SARS-CoV-2 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel in its first 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. FINDINGS: Our model was validated on a held-out set of individuals from Israel where it achieved an auROC of 0.737 (CI: 0.712–0.759) and auPR of 0.144 (CI: 0.119–0.177) and demonstrated its applicability outside of Israel in an independently collected symptom survey dataset from the US, UK, and Sweden. Our analyses revealed interactions between several symptoms and age, suggesting variation in the clinical manifestation of the disease in different age groups. CONCLUSIONS: Our tool can be used online and without exposure to suspected patients, thus suggesting worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified. Moreover, individuals at high risk for a positive test result can be isolated prior to testing. FUNDING: E.S. is supported by the Crown Human Genome Center, Larson Charitable Foundation New Scientist Fund, Else Kroener Fresenius Foundation, White Rose International Foundation, Ben B. and Joyce E. Eisenberg Foundation, Nissenbaum Family, Marcos Pinheiro de Andrade and Vanessa Buchheim, Lady Michelle Michels, and Aliza Moussaieff and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation. H.R. is supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein – Astrachan. Elsevier Inc. 2021-02-12 2020-10-10 /pmc/articles/PMC7547576/ /pubmed/33073258 http://dx.doi.org/10.1016/j.medj.2020.10.002 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical and Translational Resource and Technology Insights
Shoer, Saar
Karady, Tal
Keshet, Ayya
Shilo, Smadar
Rossman, Hagai
Gavrieli, Amir
Meir, Tomer
Lavon, Amit
Kolobkov, Dmitry
Kalka, Iris
Godneva, Anastasia
Cohen, Ori
Kariv, Adam
Hoch, Ori
Zer-Aviv, Mushon
Castel, Noam
Sudre, Carole
Zohar, Anat Ekka
Irony, Angela
Spector, Tim
Geiger, Benjamin
Hizi, Dorit
Shalev, Varda
Balicer, Ran
Segal, Eran
A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title_full A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title_fullStr A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title_full_unstemmed A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title_short A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
title_sort prediction model to prioritize individuals for a sars-cov-2 test built from national symptom surveys
topic Clinical and Translational Resource and Technology Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547576/
https://www.ncbi.nlm.nih.gov/pubmed/33073258
http://dx.doi.org/10.1016/j.medj.2020.10.002
work_keys_str_mv AT shoersaar apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT karadytal apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT keshetayya apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT shilosmadar apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT rossmanhagai apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT gavrieliamir apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT meirtomer apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT lavonamit apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT kolobkovdmitry apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT kalkairis apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT godnevaanastasia apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT cohenori apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT karivadam apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT hochori apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT zeravivmushon apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT castelnoam apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT sudrecarole apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT zoharanatekka apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT ironyangela apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT spectortim apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT geigerbenjamin apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT hizidorit apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT shalevvarda apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT balicerran apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT segaleran apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT shoersaar predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT karadytal predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT keshetayya predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT shilosmadar predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT rossmanhagai predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT gavrieliamir predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT meirtomer predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT lavonamit predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT kolobkovdmitry predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT kalkairis predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT godnevaanastasia predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT cohenori predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT karivadam predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT hochori predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT zeravivmushon predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT castelnoam predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT sudrecarole predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT zoharanatekka predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT ironyangela predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT spectortim predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT geigerbenjamin predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT hizidorit predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT shalevvarda predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT balicerran predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys
AT segaleran predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys